Arecor Therapeutics PLC
Arecor Therapeutics plc, a clinical stage biotechnology company, develops innovative medicines that address significant unmet patient needs in the United Kingdom. The company through its proprietary reformulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deli… Read more
Arecor Therapeutics PLC (AREC) - Total Liabilities
Latest total liabilities as of June 2025: GBX2.39 Million GBX
Based on the latest financial reports, Arecor Therapeutics PLC (AREC) has total liabilities worth GBX2.39 Million GBX as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Arecor Therapeutics PLC - Total Liabilities Trend (2017–2024)
This chart illustrates how Arecor Therapeutics PLC's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Arecor Therapeutics PLC Competitors by Total Liabilities
The table below lists competitors of Arecor Therapeutics PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Asiabest Group International Inc
PSE:ABG
|
Philippines | ₱1.01 Million |
|
MER
WAR:MER
|
Poland | zł19.15 Million |
|
VTXGF
PINK:VTXGF
|
USA | $143.91 Million |
|
Challenger Energy Group PLC
LSE:CEG
|
UK | GBX13.66 Million |
|
medondo holding AG
XETRA:AMI
|
Germany | €5.53 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Arecor Therapeutics PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.84 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Arecor Therapeutics PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Arecor Therapeutics PLC (2017–2024)
The table below shows the annual total liabilities of Arecor Therapeutics PLC from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | GBX3.37 Million | -42.34% |
| 2023-12-31 | GBX5.85 Million | +35.73% |
| 2022-12-31 | GBX4.31 Million | +81.70% |
| 2021-12-31 | GBX2.37 Million | -32.42% |
| 2020-12-31 | GBX3.51 Million | +219.76% |
| 2019-12-31 | GBX1.10 Million | -11.12% |
| 2019-05-31 | GBX1.23 Million | -11.56% |
| 2018-05-31 | GBX1.40 Million | +13.33% |
| 2017-05-31 | GBX1.23 Million | -- |